Log In
BCIQ
Print this Print this
 

Aerucin

  Manage Alerts
Collapse Summary General Information
Company Aridis Pharmaceuticals Inc.
DescriptionHuman IgG1 mAb against Pseudomonas aeruginosa
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationPneumonia
Indication DetailsAdjunct treatment of acute pneumonia; Treat hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa
Regulatory Designation U.S. - Fast Track (Treat hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today